FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

NCT06917313 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions

DRUG: Fezolinetant
DRUG: Placebo

Sponsor

Yale University

Collaborators

[object Object]